Also known as: Thymus Bioregulator, Crystagen Khavinson Peptide
Half-life: Short (minutes); biological effect persists via gene-expression modulation
Last reviewed: · Published:
Crystagen is a short peptide bioregulator from the Khavinson family, designed for immune-system applications. Like the closely related Thymalin and Vilon (also Khavinson family), it is proposed to target thymic and lymphocyte gene expression and restore more youthful immune function in age-related immune decline. The compound has been used in Russian clinical settings as an immunomodulator in elderly patients, in recovery from severe illness, and in chronic infectious disease contexts.
Russian clinical-observational studies have reported improvements in T-cell counts, ratios of CD4+ to CD8+ subsets, and subjective measures of immune function in elderly study populations and in patients with chronic conditions. The compound is presumed to modulate gene expression in immature thymocytes and peripheral T cells via the broader Khavinson mechanism of tissue-specific short-peptide gene regulation.
Crystagen is sold by research-chemical vendors outside Russia. Western clinical validation is essentially absent. The compound is one of several Khavinson immune-targeting bioregulators with overlapping (and somewhat redundant) clinical use cases — choice between Crystagen, Thymalin, Thymagen, and Vilon in Russian practice is often clinician-preference rather than evidence-based differentiation.
Crystagen was developed in the 2000s as one of several Khavinson short peptides aimed at the thymus and immune system. The compound entered Russian clinical observational use in elderly patient populations through the 2000s and 2010s.
Russian clinical use has reported good tolerability in elderly and chronically ill patient populations. The principal theoretical concern is the use of any immunomodulator in patients with active autoimmune disease, where shifting immune balance could in principle worsen the underlying condition. Western safety validation is essentially absent.
Dose Range
1-5 mg
Frequency
Once daily (SubQ) or sublingual
Duration
10-20 day cycles, repeated 2-3 times per year
Dosing information is for educational purposes only. Consult a healthcare professional before using any peptide.
Typical Vial Size
20 mg
Water Type
Bacteriostatic water (BAC water)
Mixing Volume
2 mL
Half-Life
Short (minutes); biological effect persists via gene-expression modulation
Molecular Weight
~400-500 Da
Store reconstituted vial refrigerated at 2-8°C. Use within 21-30 days. Sublingual or subcutaneous administration is typical.
Disclosure: PinnyPeptide may earn a commission on purchases made through the links above, at no extra cost to you. We only list vendors we're willing to point our community at, but inclusion is not a clinical endorsement. Always verify each vendor's third-party testing and your local legal status before purchasing.
FDA Status
Not FDA approved.
Legal Status
Unregulated research chemical outside Russia.
USA
Not approvedResearch-only
EU
Not approvedNot authorized as medicinal product
UK
Not approvedClassified as research chemical
Russia
Used in clinical practiceUsed as bioregulator in Russian geriatric and infectious-disease medicine
Australia
Not approvedTGA has not evaluated
Canada
Not approvedNot authorized for human use
Khavinson VK, Kuznik BI, Tarnovskaya SI, Linkova NS
Bulletin of Experimental Biology and Medicine (2015)
Foundational Khavinson-group review covering the immune-targeting bioregulators including Crystagen.
View Study →Khavinson VK, Kuznik BI, Linkova NS, Trofimova SV
Advances in Gerontology (2017)
Russian-group review of thymic peptide bioregulators including Crystagen in the context of immune senescence, framing the therapeutic rationale for clinical use in elderly populations.
View Study →Khavinson VK, Anisimov VN, Linkova NS, Bakhmet AA
Bulletin of Experimental Biology and Medicine (2020)
Modern Khavinson-group mechanistic review applicable to immune-targeting bioregulators including Crystagen.
View Study →Original Khavinson thymic peptide complex — multi-peptide immunomodulator with 40-year Russian clinical track record.
Khavinson short peptide bioregulator targeting thymic function — Glu-Trp synthetic version.
Khavinson Lys-Glu dipeptide — immunomodulator with documented life-extension activity in mice.
Thymic peptide with broad immunomodulatory activity, approved in over 35 countries.
Track Crystagen and more with PinnyPeptide.
Sign Up to Track CrystagenFree forever · defaults pre-filled from this article